A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Locations

Australia, Canada, Germany, Poland, Puerto Rico, Romania, Slovakia, United States

Start date

11/08/2025

Identifiers

Trial ID NN1436-8182,
NCT number NCT07076199,
Eudract number Not Available

Summary

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Trial Overview:

Condition

Diabetes Mellitus, Type 1

Treatment

DRUG: Insulin icodec

DRUG: Insulin glargine

DRUG: Insulin aspart

Study type

INTERVENTIONAL

Trial duration

Aug 11 2025 - Dec 28 2026

Participants

877

Phase

III

Are you eligible?

Gender

Male and female

Age

18 years and older

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

Find answers in our FAQs

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.